VetSheet

마르보플록사신

Marbofloxacin

Ro 9-1168

플루오로퀴놀론계 항생제POIVSCTopical개고양이파충류

다른 이름: Zeniquin · Marbocyl · Aurizon · Efex · Marbocare · Ro 9-1168 · Marbofloxacine · Marbofloxacinum · Marbofloxacino

VetSheet 수의사 팀 검수업데이트 2026년 4월 5일근거 기반 수의학 참고자료

WHO 최우선 중요 항생제 — 신중하게 사용하고 불필요한 처방 회피
2.75-5.5 mg/kg PO once dailyPO· q24h· Give for 2-3 days beyond cessation of clinical signs (skin/soft tissue); at least 10 days (urinary tract). Max 30 days.
— 🐕

용량은 수의사 전문가를 위한 임상 참고자료입니다. 반드시 최신 약물 정보 및 개별 환자에 따라 확인하시기 바랍니다.

동물 종별 용량

🌎 NA — North America🌍 EU — Europe

개

적응증용량경로빈도기간지역
For susceptible infections (urinary tract, skin and soft tissue)2.75-5.5 mg/kg PO once dailyPOq24hGive for 2-3 days beyond cessation of clinical signs (skin/soft tissue); at least 10 days (urinary tract). Max 30 days.🌎 NA
For susceptible Pseudomonas otitis5.5 mg/kg PO once dailyPOq24h—🌎 NA
Susceptible bacterial infections2 mg/kgIV/SC/POq24hNot specified🌍 EU
Otitis externa10 drops per eartopicalsidNot specified🌍 EU
  • For susceptible infections (urinary tract, skin and soft tissue): If no improvement noted after 5 days, reevaluate diagnosis.
  • For susceptible Pseudomonas otitis: Dose at the high end of the flexible dosing label for severe/chronic cases or when topical therapy is not possible.
  • Susceptible bacterial infections: Higher doses should be considered for certain sites, including prostatitis, and for certain isolates of Pseudomonas aeruginosa.
  • Otitis externa: Using compound aural preparation.

고양이

적응증용량경로빈도기간지역
For susceptible infections (urinary tract, skin and soft tissue)2.75-5.5 mg/kg PO once dailyPOq24hGive for 2-3 days beyond cessation of clinical signs (skin/soft tissue); at least 10 days (urinary tract). Max 30 days.🌎 NA
First-line treatment for feline tuberculosis or non-tuberculous mycobacteria (NTM)2 mg/kg PO once dailyPOq24h—🌎 NA
For hemoplasmosis2.75 mg/kg PO once daily (q24h)POq24h—🌎 NA
Susceptible bacterial infections2 mg/kgIV/SC/POq24hNot specified🌍 EU
  • For susceptible infections (urinary tract, skin and soft tissue): If no improvement noted after 5 days, reevaluate diagnosis.
  • First-line treatment for feline tuberculosis or non-tuberculous mycobacteria (NTM): Pending definitive diagnosis. Not effective against MAC infection.
  • Susceptible bacterial infections: Do not use 20 mg or 80 mg tablets. May allow clearance of Mycoplasma haemofelis in persistently infected cats.

파충류

적응증용량경로빈도기간지역
Susceptible infections10 mg/kg PO at least every 48 hoursPOq48h—🌎 NA
  • Susceptible infections: Study done in Ball pythons (Python regius). Further studies required to determine effective doses and toxicity.

용량은 수의사 전문가를 위한 임상 참고자료입니다. 반드시 최신 약물 정보 및 개별 환자에 따라 확인하시기 바랍니다.

진료 중이신가요? VetSheet의 AI가 약물, 용량, 투여 기간을 구조화된 진료 기록에 바로 기입합니다.VetSheet 작동 방식 보기

개요

​마르보플록사신(Marbofloxacin)​은 주로 수의학에서 사용되는 합성 광범위 ​플루오로퀴놀론계 항생제​입니다. 그람 음성균 및 그람 양성균 모두에 대해 ​농도 의존적 살균 활성​과 유의미한 ​항생제 후 효과(PAE)​를 나타냅니다. 세균 복제의 정지기 및 성장기 모두에서 활성을 보입니다.

  • ​항균 스펙트럼​: 다양한 그람 음성 간균 및 구균(예: 녹농균, 대장균, 클레브시엘라, 엔테로박터, 프로테우스, 살모넬라)과 일부 그람 양성균(예: 페니실리나아제 생성 균주를 포함한 포도상구균)에 매우 효과적입니다.
  • ​임상 요점​: 다른 플루오로퀴놀론계와 마찬가지로 대부분의 혐기성 세균에 대한 활성이 약하며 연쇄상구균에 대한 효능은 다양하거나 떨어집니다. 혐기성 또는 연쇄상구균 감염에는 권장되지 않습니다.
  • ​내성​: 주로 염색체 돌연변이(특히 녹농균, 클레브시엘라, 장구균)를 통해 발생하며, 플라스미드 매개 내성은 드뭅니다.

작용 기전

Marbofloxacin exerts its bactericidal effect by targeting key bacterial enzymes involved in DNA replication and transcription:

  • Inhibits DNA-gyrase (topoisomerase II) → prevents DNA supercoiling.
  • Inhibits Topoisomerase IV → prevents separation of interlinked daughter DNA molecules.
  • Result: Disruption of DNA replication, transcription, and repair → rapid bacterial cell death (typically within 20-30 minutes of exposure).

안전성·주의사항

금기사항

  • Hypersensitivity to fluoroquinolones
  • Small and medium breed dogs up to 8 months of age
  • Large breed dogs up to 12 months of age
  • Giant breed dogs up to 18 months of age
  • Cats under 12 months of age
  • Food-producing animals (FDA prohibited)
  • Cats (do not use 20 mg and 80 mg tablets)
  • Dogs < 12 months of age
  • Giant-breed dogs < 18 months of age
  • Cats < 16 weeks of age

부작용

  • Gastrointestinal distress (vomiting, anorexia, soft stools, diarrhea)
  • Decreased activity/lethargy
  • Cartilage abnormalities in young, growing animals
  • Elevated hepatic enzymes (rare)
  • Ataxia, seizures, depression, nervousness (rare)
  • Hypersensitivity reactions (rare)
  • Crystalluria (rare)
  • Potential ocular toxicity/blindness in cats (rare/unproven, but reported)
  • Gastrointestinal signs (nausea, vomiting)
  • Potential CNS toxicity (seizures)
  • Cartilage abnormalities in growing animals
  • Potential retinal toxicity/blindness in cats (at high doses)

주의

Warning: Contraindicated in young, growing animals due to the risk of articular cartilage lesions (arthropathy).

  • Neurologic: Can rarely cause CNS stimulation; use with caution in patients with pre-existing seizure disorders.
  • Renal/Hepatic: Use cautiously in patients with severe hepatic or renal insufficiency.
  • Hydration: Ensure adequate hydration to minimize the risk of crystalluria.
  • Regulatory: The FDA strictly prohibits the extra-label use of fluoroquinolones in food-producing animals.

약물 상호작용

Antacids / Dairy Products

Cations (Mg++, Al+++, Ca++) may bind to marbofloxacin and prevent its absorption; separate doses by at least 2 hours

Antibiotics (aminoglycosides, 3rd-gen cephalosporins, extended-spectrum penicillins)

Unpredictable synergism may occur against some bacteria, particularly Pseudomonas aeruginosa

Cyclosporine

May exacerbate nephrotoxicity and reduce the metabolism of systemically used cyclosporine

Flunixin

May increase AUC and elimination half-life of the fluoroquinolone, and vice versa (extrapolated from enrofloxacin)

Glyburide

Severe hypoglycemia possible

Iron, Zinc (oral)

Decreased marbofloxacin absorption; separate doses by at least two hours

Methotrexate

Increased MTX levels possible with resultant toxicity

Nitrofurantoin

May antagonize the antimicrobial activity of fluoroquinolones; concomitant use not recommended

Phenytoin

Marbofloxacin may alter phenytoin levels

Probenecid

Blocks tubular secretion and may increase blood level and half-life of marbofloxacin

Quinidine

Increased risk for cardiotoxicity

SucralfateMajor

May inhibit absorption of marbofloxacin; separate doses by at least 2 hours

TheophyllineMajor

May increase theophylline blood levels (though less likely than with enrofloxacin)

Warfarin

Potential for increased warfarin effects

Antacids (Mg2+, Al3+)Major

Bind fluoroquinolones, preventing GI absorption

Zinc saltsModerate

Inhibits absorption (separate dosing by at least 2 hours)

CimetidineModerate

May reduce the clearance of fluoroquinolones

CiclosporinMajor

May decrease metabolism and increase nephrotoxicity

TacrolimusMajor

May decrease metabolism and increase nephrotoxicity

Oral anticoagulantsMajor

May increase anticoagulant action

NSAIDsMajor

May potentiate CNS adverse effects (seizures)

모니터링

  • Clinical efficacy (resolution of infection)
  • Adverse effects (GI distress, CNS signs)
  • Joint health/lameness in younger animals (if inadvertently used)
  • Clinical efficacy and resolution of infection
  • Culture and susceptibility results
  • Signs of gastrointestinal upset
  • Neurological signs (especially in patients with a history of seizures)
  • Vision changes or mydriasis in cats

약동학

반감기

고양이~13 hours개9-12 hours

흡수

Dogs: Rapidly absorbed after oral administration with 94% bioavailability; peak plasma levels in ~1.5 hours. Cats: Absorption is nearly complete; peak serum levels in 1-2 hours.

분포

Dogs: Apparent volume of distribution is 1.2-1.9 L/kg. Protein binding is low.

대사

Dogs: Only about 15% of a dose is metabolized in the liver.

배설

Dogs: Eliminated unchanged in the urine (40%) and bile/feces.

과다투여

Acute overdoses of marbofloxacin are unlikely to result in signs more serious than anorexia or vomiting, though other adverse effects (like CNS stimulation) could theoretically occur.

  • Chronic Toxicity: In safety studies, dogs receiving massive overdoses (55 mg/kg per day for 12 days) developed anorexia, vomiting, dehydration, tremors, red skin, facial swelling, lethargy, and weight loss.
  • Treatment: Management of overdose consists of drug withdrawal and symptomatic/supportive care. If ingestion was recent, gastrointestinal decontamination (emesis or activated charcoal) may be considered.

제품

제형

  • Oral tablets
  • Injectable: 200 mg powder for reconstitution (10 mg/ml)
  • Oral: 5 mg, 20 mg, 80 mg tablets
  • Topical: 3 mg/ml aural drops (compound with clotrimazole and dexamethasone)

동물용의약품

  • Marbofloxacin Oral Tablets: 25 mg, 50 mg, 100 mg, 200 mg (Zeniquin)
  • Actimarbo
  • Aurizon
  • Efex
  • Marbocare
  • Marbocyl
  • Marbodex
  • Marbotab
  • Marboxidin
  • Marfloquin
  • NorOtic
  • Quiflor
  • Softiflox
  • Ubiflox

규제 현황

European Union✓ 승인됨처방전의약품EMA
🐕 Dogs🐈 Cats🐄 Cattle pigs

POM-V classification.

United Kingdom✓ 승인됨처방전의약품VMD
🐕 Dogs🐈 Cats

POM-V classification.

규제 데이터 없음: 🇺🇸 US · 🇭🇰 HK · 🇹🇼 TW · 🇯🇵 JP · 🇰🇷 KR · 🇦🇺 AU

보관·안정성

Marbofloxacin tablets should be stored below 30°C (86°F).

보호자 정보

  • ​치료 과정 완료​: 수의사가 처방한 대로 정확하게 약을 투여하세요. 반려동물이 다 나은 것 같다고 해서 임의로 투약을 중단하지 마세요. 일찍 중단하면 내성균 감염이 발생할 수 있습니다.
  • ​투여 방법​: 음식과 함께 또는 빈속에 투여할 수 있습니다. 구토를 하는 경우 소량의 간식이나 사료와 함께 먹여보세요.
  • ​유제품 및 영양제 피하기​: 이 약을 유제품(치즈, 우유), 제산제 또는 철분/아연 영양제와 동시에 먹이지 마세요. 이러한 성분은 약물과 결합하여 흡수를 방해할 수 있습니다. 최소 2시간의 간격을 두고 투여하세요.
  • ​부작용 관찰​: 심한 구토, 설사, 식욕 부진 또는 이상 행동(떨림, 비틀거림, 갑작스러운 무기력증 등)이 관찰되면 수의사에게 연락하세요.

VetSheet 의약품 참고자료는 수의사 전문가의 임상 의사결정 지원을 위한 것이며, 전문적 판단이나 제조사의 최신 약물 정보를 대체할 수 없습니다.